[Use of antibiotics in chronic bronchitis]

Whether it is advisable to use tarivide, a wide-spectrum acting antibiotic, in 193 patients aged 23 to 50 years who had chronic catarrhal bronchitis. The experimental group included 43 and 57 patients with chronic nonobstructive and obstructive bronchitis, respectively. For comparison, a matched group receiving penicillin comprised 40 and 53 patients, respectively. Tarivide eliminated most strains of pathogens and improves cellular immunity. Cure and improvement were achieved in 147 (77%) and 13 (12%) patients, respectively. The favourable pharmacokinetics of tarivide, its easy-to-use regimen make it the drug of choice for oral treatment.